Chr. Hansen Holding A/S

Chr. Hansen is a biosciences group based in Denmark. Co. develops and supplies natural ingredient solutions for the food, pharmaceutical, nutritional, and agricultural industries worldwide. Co. operates in three divisions: Cultures and Enzymes (develops, produces, and sells cultures, enzymes, and probiotics for the food and dairy industries); Health and Nutrition (develops products for the dietary supplement, over-the-counter pharmaceutical, infant formula, and animal feed industries); and Natural Colors (develops natural color solutions to the food industry, primarily for the beverage, dairy, confectionery, fruit preparation and ice cream, as well as functional blends for processed meats).
  • TickerCHR
  • ISINDK0060227585
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

CHR HANSEN HOLDING AS sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CHR HANSEN HOLDING AS (DK), active in the Food Products industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date June 28, 2019, the closing price was DKK 616.40 and its target price was estimated at DKK 585.58.

Ioannis Pontikis

Morningstar | Chr. Hansen Reports 3Q Results, Lowers Organic Growth Guidance for the Year; Shares Still Rich

Chr. Hansen reported third-quarter and nine-month results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 9% (6% volume, 3% pricing), respectively, slightly lower than our full-year estimates. The company also reduced fiscal 2019 organic revenue growth guidance for the group to 7%-8% from 9%-11%, owing to more challenging trading conditions in emerging markets (natural colors), negative growth of the food cultures and enzymes business in China, and continued underperformance of the animal health business. That said, Chr. Hansen left its long-term group guidance of 8%-...

Ioannis Pontikis

Morningstar | Chr. Hansen Reports 3Q Results, Lowers Organic Growth Guidance for the Year; Shares Still Rich. See Updated Analyst Note from 27 Jun 2019

Chr. Hansen reported third-quarter and nine-month results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 9% (6% volume, 3% pricing), respectively, slightly lower than our full-year estimates. The company also reduced fiscal 2019 organic revenue growth guidance for the group to 7%-8% from 9%-11%, owing to more challenging trading conditions in emerging markets (natural colors), negative growth of the food cultures and enzymes business in China, and continued underperformance of the animal health business. That said, Chr. Hansen left its long-term group guidance of 8%-...

Ioannis Pontikis

Chr. Hansen Reports 3Q Results, Lowers Organic Growth Guidance for the Year; Shares Still Rich

Chr. Hansen reported third-quarter and nine-month results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 9% (6% volume, 3% pricing), respectively, slightly lower than our full-year estimates. The company also reduced fiscal 2019 organic revenue growth guidance for the group to 7%-8% from 9%-11%, owing to more challenging trading conditions in emerging markets (natural colors), negative growth of the food cultures and enzymes business in China, and continued underperfor...

Ioannis Pontikis

Morningstar | Chr. Hansen Reports 3Q Results, Lowers Organic Growth Guidance for the Year; Shares Still Rich

Chr. Hansen reported third-quarter and nine-month results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 9% (6% volume, 3% pricing), respectively, slightly lower than our full-year estimates. The company also reduced fiscal 2019 organic revenue growth guidance for the group to 7%-8% from 9%-11%, owing to more challenging trading conditions in emerging markets (natural colors), negative growth of the food cultures and enzymes business in China, and continued underperformance of the animal health business. That said, Chr. Hansen left its long-term group guidance of 8%-...

Ioannis Pontikis

Morningstar | Chr. Hansen Reports 3Q Results, Lowers Organic Growth Guidance for the Year; Shares Still Rich. See Updated Analyst Note from 27 Jun 2019

Chr. Hansen reported third-quarter and nine-month results for fiscal 2019 with group sales growth of 8% (6% volume, 2% pricing) and 9% (6% volume, 3% pricing), respectively, slightly lower than our full-year estimates. The company also reduced fiscal 2019 organic revenue growth guidance for the group to 7%-8% from 9%-11%, owing to more challenging trading conditions in emerging markets (natural colors), negative growth of the food cultures and enzymes business in China, and continued underperformance of the animal health business. That said, Chr. Hansen left its long-term group guidance of 8%-...

3 directors bought

Three Directors at Chr.Hansen Holding AS bought 5,300 shares at between 610.000DKK and 628.210DKK. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under l...

Christer Magnergård ...
  • Frank Maaø
  • Martin Arnell
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Frank Maaø ...
  • Martin Arnell
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

CHR HANSEN HOLDING AS sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CHR HANSEN HOLDING AS (DK), active in the Food Products industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date June 28, 2019, the closing price was DKK 616.40 and its target price was estimated at DKK 585.58.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch